xs sm md lg

While pharmaceutical revenues are traditionally derived from a few products that are heavily marketed, decreasing R&D productivity together with pricing and reimbursement hurdles are driving change in the industry. The emergence of novel and advanced therapies is also creating new opportunities. Economic expansion and increasing affluence in the emerging markets are other factors driving growth in both prescription and over-the-counter drug markets.

Our specialist teams of risk engineers partner with the Swiss Re Institute to ensure our knowledge and expertise of Pharmaceutical industry remains highly relevant and insightful for our clients and brokers. A tool for reaching this goal are our Casualty Risk Trends report, which aim at supporting your underwriting decisions, helping you to focus on the right risks at the right time.

You can download the Pharmaceutical industry report here!

Don't miss also our other casualty risk trends reports:

Dorothea  Koppe
  • PDF
    109 KB

    Casualty Risk Trends: Pharmaceutical industry

View more
  • PDF
    109 KB

    Casualty Risk Trends: Pharmaceutical industry